The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study-Reference-Cited by-同舟云学术

The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study

Published:2020-03 Issue:2 Volume:14 Page:225-238
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Nozaki Akito^ORCID, ,Atsukawa Masanori,Kondo Chisa,Toyoda Hidenori,Chuma Makoto,Nakamuta Makoto,Uojima Haruki,Takaguchi Koichi,Ikeda Hiroki,Watanabe Tsunamasa,Ogawa Shintaro,Itokawa Norio,Arai Taeang,Hiraoka Atsushi,Asano Toru,Fujioka Shinichi,Ikegami Tadashi,Shima Toshihide,Ogawa Chikara,Akahane Takehiro,Shimada Noritomo,Fukunishi Shinya,Abe Hiroshi,Tsubota Akihito,Genda Takuya,Okubo Hironao,Mikami Shigeru,Morishita Asahiro,Moriya Akio,Tani Joji,Tachi Yoshihiko,Hotta Naoki,Ishikawa Toru,Okanoue Takeshi,Tanaka Yasuhito,Kumada Takashi,Iwakiri Katsuhiko,Maeda Shin

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-020-10019-z.pdf

Reference44 articles.

1. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017;377:1448–1555

2. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017;67:263–271

3. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062–1068

4. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354–369

5. Wyles D, Poordad F, Wang S, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 2017;67:514–523

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis;Journal of Gastroenterology;2024-05-10

2. Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma;Biomarkers;2024-02-15

3. A single site study to investigate the current prevalence of anti‐hepatitis C virus antibody among substance use disorder patients in Hiroshima—Insufficient testing and diagnosis;Neuropsychopharmacology Reports;2023-05-16

4. The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital;BMC Gastroenterology;2023-04-11

5. Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid;Viruses;2023-02-09